1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Legislation

US VMS Industry Makes Lame Duck Session List, Checks It Twice For MPL Language

 
• By Malcolm Spicer

AHPA urges chairs and ranking members of Senate HELP and House Energy and Commerce committees not to pass mandatory product listing legislation or make other changes to FDA regulation of industry before the 117th Congress ends. NPA board members lobby lawmakers about the topic.

• Source: Shutterstock

US dietary supplement industry groups are making a list of gifts they don’t want delivered during Congress’s lame duck session and are checking it twice by reminding lawmakers about their concerns.

The American Herbal Products Association urges the chairs and ranking members of congressional committees with oversight of the Food and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

US Tax Code Already Spells Using HSA/FSAs For Dietary Supplement Purchases, NPA Tells IRS

 
• By Malcolm Spicer

Internal Revenue Code should include within its definition of “medical care” spending the consumers' purchases of supplement products based on labeling of FDA-approved health and structure/function claims, NPA CEO Daniel Fabricant says.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Utah Delegation’s Support For Supplement Industry Key For Caucus Restart In Congress

 
• By Malcolm Spicer

Dietary Supplement Caucus e-launched the 119th Congress with Utah Republican House member Mike Kennedy and Texas Democrat member Marc Veasey as co-chairs and with a total of nine senators and 20 House members spanning both parties.

Price To Resolve US Hemp Dilemma Too High In House Appropriators’ FY 2026 FDA Spending Bill

 
• By Malcolm Spicer

Provisions in bill approved by Agriculture, Rural Development, FDA and Related Agencies Subcommittee aren’t likely to pass largely because they set a price too high for delta-8 THC and other ingredients to meet the definition of hemp as a de-scheduled substance.

More from Policy & Regulation

US FDA’s Kratom Focus Pivots To ‘Concentrated Synthetic Byproduct That Is An Opioid’

 
• By Malcolm Spicer

Explaining he was a heroin addict for 14 years more than 40 years ago “because it was so available,” Secretary Kennedy says “our agencies have been asleep in the wheel” but “now we're going to wake up and we're going to start to stop this before it starts.”

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

US FDA Extracts More Evidence To Ban Kratom

 
• By Malcolm Spicer

Recent warning letters to seven companies marketing products with kratom extract known as 7-OH are FDA’s first in three years referencing unlawful products containing kratom and the first of all its kratom-related warnings to reference extracts from the botanical.